An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
| Autor: | Arkenau, H.-T., Italiano, A., Mak, G., Toulmonde, M., Baird, R.D., Garcia-Corbacho, J., Plummer, R., Flynn, M., Forster, M., Wilson, R.H., Tosi, D., Adenis, A., Donaldson, K., Posner, J., Kawabata, I., Arimura, A., Deva, S., Spicer, J. |
|---|---|
| Zdroj: | In European Journal of Cancer November 2018 103:17-23 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect